Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study.

Subcutaneous bremelanotide (a melanocortin receptor agonist closely related to Melanotan-II) produced statistically significant improvements in erectile response in men who had failed sildenafil therapy.

Investigated as a clinical (randomized double-blind, men with erectile dysfunction) in the field of dermatological research. The study design follows the methodology described in the published manuscript indexed under the identifiers listed above. Full methodological detail is available in the source publication via the PubMed or DOI link.

Subcutaneous bremelanotide (a melanocortin receptor agonist closely related to Melanotan-II) produced statistically significant improvements in erectile response in men who had failed sildenafil therapy.

Bremelanotide is a related but distinct molecule; results do not directly establish efficacy or safety of Melanotan-II itself.

• · PubMed: PMID 18206919 ↗
• · DOI: 10.1016/j.juro.2007.10.063 ↗
• · PubMed search by title: pubmed.ncbi.nlm.nih.gov ↗
• · Google Scholar: scholar.google.com ↗